Florian Brand, atai Life Sciences CEO

Atai Life Sci­ences spot­lights ear­ly de­pres­sion da­ta for psy­che­del­ic ahead of big read­out

Less than two months af­ter bet­ting $50 mil­lion on Beck­ley Psytech’s psy­che­del­ic drugs, atai Life Sci­ences has shared ini­tial Phase 2a re­sults for one can­di­date …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.